Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer.
Kok M, Gielen RJ, Adams S, Lennerz JK, Sharma P, Loibl S, Reardon E, Sonke G, Linn S, Delaloge S, Lacombe D, Robinson T, Badve S, Martin M, Balko JM, Ignatiadis M, Curigliano G, Wolff AC, Mittendorf EA, Loi S, Pusztai L, Tolaney SM, Salgado R. Kok M, et al. Among authors: mittendorf ea. J Clin Oncol. 2024 Oct 20;42(30):3523-3529. doi: 10.1200/JCO.24.00372. Epub 2024 Jul 22. J Clin Oncol. 2024. PMID: 39038259 No abstract available.
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.
Spring LM, Tolaney SM, Fell G, Bossuyt V, Abelman RO, Wu B, Maheswaran S, Trippa L, Comander A, Mulvey T, McLaughlin S, Ryan P, Ryan L, Abraham E, Rosenstock A, Garrido-Castro AC, Lynce F, Moy B, Isakoff SJ, Tung N, Mittendorf EA, Ellisen LW, Bardia A. Spring LM, et al. Among authors: mittendorf ea. Ann Oncol. 2024 Mar;35(3):293-301. doi: 10.1016/j.annonc.2023.11.018. Epub 2023 Dec 12. Ann Oncol. 2024. PMID: 38092228
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer.
Guerriero JL, Lin JR, Pastorello RG, Du Z, Chen YA, Townsend MG, Shimada K, Hughes ME, Ren S, Tayob N, Zheng K, Mei S, Patterson A, Taneja KL, Metzger O, Tolaney SM, Lin NU, Dillon DA, Schnitt SJ, Sorger PK, Mittendorf EA, Santagata S. Guerriero JL, et al. Among authors: mittendorf ea. NPJ Breast Cancer. 2024 Jan 2;10(1):2. doi: 10.1038/s41523-023-00605-3. NPJ Breast Cancer. 2024. PMID: 38167908 Free PMC article.
Neoadjuvant Immunotherapy-From Trials to Practice.
Mittendorf EA, Tolaney SM. Mittendorf EA, et al. JAMA Oncol. 2024 Oct 1;10(10):1319-1321. doi: 10.1001/jamaoncol.2024.2924. JAMA Oncol. 2024. PMID: 39207783 No abstract available.
Concordance of PD-L1 Expression in Metastatic Triple-negative Breast Cancer Between the 22C3 and E1L3N Antibodies Using Combined Positive Scoring.
Erick TK, Lester SC, Garrido-Castro AC, Hughes M, Cunningham O, Lin NU, Mittendorf EA, Tolaney SM, Brock JE. Erick TK, et al. Among authors: mittendorf ea. Appl Immunohistochem Mol Morphol. 2024 Oct 1;32(9):417-424. doi: 10.1097/PAI.0000000000001223. Epub 2024 Sep 20. Appl Immunohistochem Mol Morphol. 2024. PMID: 39351784
[No title available]
[No authors listed] [No authors listed] PMID: 37985526
[No title available]
[No authors listed] [No authors listed] PMID: 38206504
ASO Visual Abstract: Real-World Implications of the SOUND Trial.
Giannakou A, Kantor O, Park KU, Waks AG, Punglia RS, Dominici LS, Nakhlis F, Mittendorf EA, King TA. Giannakou A, et al. Among authors: mittendorf ea. Ann Surg Oncol. 2024 Nov 9. doi: 10.1245/s10434-024-16465-5. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39521738
373 results